Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records.
Beaufils M, Amodru V, Tejeda M, Boher JM, Zemmour C, Chanez B, Chrétien AS, Gorvel L, Gravis G, Bruyat D, Mari R, Madroszyk A, Cuny T, Gonçalves A, Lisberg AE, Olive D, Tassy L, Castinetti F, Rochigneux P. Beaufils M, et al. Among authors: zemmour c. J Immunother Cancer. 2023 Aug;11(8):e006786. doi: 10.1136/jitc-2023-006786. J Immunother Cancer. 2023. PMID: 37536938 Free PMC article.
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G. de Nonneville A, et al. Among authors: zemmour c. Breast Cancer Res Treat. 2017 Apr;162(2):307-316. doi: 10.1007/s10549-017-4136-5. Epub 2017 Feb 2. Breast Cancer Res Treat. 2017. PMID: 28155054
Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A, Gonçalves A, Zemmour C, Cohen M, Classe JM, Reyal F, Colombo PE, Jouve E, Giard S, Barranger E, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G. de Nonneville A, et al. Among authors: zemmour c. Eur J Cancer. 2017 Oct;84:34-43. doi: 10.1016/j.ejca.2017.06.043. Epub 2017 Aug 4. Eur J Cancer. 2017. PMID: 28780480
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.
Monneur A, Goncalves A, Gilabert M, Finetti P, Tarpin C, Zemmour C, Extra JM, Tallet A, Lambaudie E, Jacquemier J, Houvenaeghel G, Boher JM, Viens P, Bertucci F. Monneur A, et al. Among authors: zemmour c. Oncotarget. 2017 Jul 31;8(39):66019-66032. doi: 10.18632/oncotarget.19732. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029489 Free PMC article.
Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A. Sabatier R, et al. Among authors: zemmour c. Cancer Res Treat. 2018 Oct;50(4):1226-1237. doi: 10.4143/crt.2017.446. Epub 2017 Dec 28. Cancer Res Treat. 2018. PMID: 29281873 Free PMC article.
Impact of a computer-assisted decision support system (CDSS) on nutrition management in critically ill hematology patients: the NUTCHOCO study (nutritional care in hematology oncologic patients and critical outcome).
Ettori F, Henin A, Zemmour C, Chow-Chine L, Sannini A, Bisbal M, Gonzalez F, Servan L, de Guibert JM, Faucher M, Boher JM, Mokart D. Ettori F, et al. Among authors: zemmour c. Ann Intensive Care. 2019 May 7;9(1):53. doi: 10.1186/s13613-019-0527-6. Ann Intensive Care. 2019. PMID: 31065880 Free PMC article.
PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.
Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M, Gonçalves A. Bertucci A, et al. Among authors: zemmour c. Front Oncol. 2020 Nov 25;10:575978. doi: 10.3389/fonc.2020.575978. eCollection 2020. Front Oncol. 2020. PMID: 33330051 Free PMC article.
Endoscopic management of concomitant biliary and duodenal malignant obstruction: Impact of the timing of drainage for one vs. two procedures and the modalities of biliary drainage.
Debourdeau A, Caillol F, Zemmour C, Winkler JP, Decoster C, Pesenti C, Ratone JP, Boher JM, Giovannini M. Debourdeau A, et al. Among authors: zemmour c. Endosc Ultrasound. 2021 Mar-Apr;10(2):124-133. doi: 10.4103/EUS-D-20-00159. Endosc Ultrasound. 2021. PMID: 33818527 Free PMC article.
Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
Gravis G, Autret A, Guibert-Broudic M, Dubergé T, Zemmour C, Carrier P, Salem N, Badinand D, Cartier L, Gross E, Walz J, Pignot G, Brenot-Rossi I. Gravis G, et al. Among authors: zemmour c. Clin Genitourin Cancer. 2021 Aug;19(4):346-353. doi: 10.1016/j.clgc.2021.03.004. Epub 2021 Mar 16. Clin Genitourin Cancer. 2021. PMID: 33849812
57 results